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CASE REPORT
Plasmodium vivax cerebral malaria 
in an adult patient in Sudan
Maowia M. Mukhtar1*, Omer A. Eisawi2, Seth A. Amanfo3, Elwaleed M. Elamin1, Zeinab S. Imam1, 
Faiza M. Osman4 and Manasik E. Hamed1
Abstract 
Background: Plasmodium vivax infection is rising in sub-Saharan Africa, where Plasmodium falciparum is responsible 
for more than 90% of malaria cases. While P. vivax is identified as a major cause of severe and cerebral malaria in South 
east Asia, the Pacific and South America, most of the severe and cerebral cases in Africa were attributed to P. falcipa-
rum. Cases of severe malaria due to P. vivax are emerging in Africa. A few severe P. vivax cases were reported in Eastern 
Sudan and they were underestimated due to the lack of accurate diagnosis, low parasitaemia and seldom use of rapid 
diagnostic tests (RDTs).
Case presentation: A 60-year-old Sudanese male presented to the Al Kuwaiti hospital in the Sudan capital Khar-
toum. On admission, the patient was complaining of fever (measured temperature was 38 °C), sweating, chills, 
vomiting and confusion in the past 2 days prior to his admission. He rapidly deteriorated into a coma state within 
48 h of the admission, with significant neck stiffness. He was admitted to the intensive care unit and was suspected of 
meningitis. Lumbar puncture was not performed since the patient was suffering from spinal cord disc. Brain CT scan 
was unremarkable. Several biochemical, haematological tests, and blood film for malaria were performed. The results 
of the laboratory tests were within the normal range except of mild elevation of the total white blood cell count and a 
significant decrease in the platelets count. Malaria parasites were seen in the blood film with high parasitaemia (quan-
tified as 3 +++). The patient was diagnosed as P. vivax cerebral malaria based on the positive blood film and the 
amplification of P. vivax specific 499 bp amplicon using Plasmodium multi-species multiplex Polymerase Chain Reac-
tion (PCR). The patient was treated with quinine 10 mg/kg body weight for 10 days followed by primaquine 15 mg/
days PO for 2 weeks. The symptoms subsided within 48 h and the patients was cured and released from the hospital.
Conclusions: Plasmodium vivax is an emerging cause of cerebral malaria in adults in Sudan and should be consid-
ered in the differential diagnosis of cerebral malaria for proper management of patients.
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Background
Plasmodium vivax infection is geographically widely 
spread. In 2013, it comprised 8% of all estimated malaria 
cases globally, and represented 47% of cases outside sub-
Saharan Africa, and < 1% of cases in the WHO African 
Region [1]. According to the World Health Organiza-
tion (WHO), there were about 15.8 million P. vivax cases 
in 2013, with the total number of malaria deaths that 
could be attributed to P. vivax ranging between 1900 and 
10,000 globally.
Severe cases and deaths due to P. vivax malaria were 
reported from all endemic regions. In 2015, severe 
vivax malaria was attributed to cause 16% of all malaria 
related mortality outside sub-Saharan Africa [2]. The risk 
of death from P. vivax malaria was estimated ranging 
between 0.012 and 0.063%, while the risk of severe dis-
ease was estimated between 0.29 and 0.82% [2].
Plasmodium vivax infection is an emerging public 
health problem in Sudan with an overall prevalence of 
26.6% among malaria cases in different regions of the 
Open Access
Malaria Journal
*Correspondence:  mmukhtar@tropmedicine.org
1 Bioscience Research Institute, Ibn Sina University, P.O. Box 11463, 
Khartoum, Sudan
Full list of author information is available at the end of the article
Page 2 of 3Mukhtar et al. Malar J          (2019) 18:316 
country [3]. Severe P. vivax cases were mostly neglected 
and misdiagnosed as Plasmodium falciparum infection 
or confused with other fever causing disease. There were 
a few reports of severe P. vivax malaria cases in Sudan, 
suggesting an underestimation of the prevalence of 
severe P. vivax infection due to the low sensitivity of the 
currently used blood films and the seldom use of rapid 
diagnostic tests (RDT) [4–6].
There is a need for accurate and rapid diagnosis of 
severe P. vivax infection for differential diagnosis form 
P. falciparum cerebral cases for effective management of 
patients.
Case presentation
A 60-year-old Sudanese male presented to the Al Kuwaiti 
hospital in the Sudan capital Khartoum complaining of 
fever (measured temperature was 38 °C) associated with 
sweating, chills, vomiting and confusion for 2 days prior 
to admission. He had been diagnosed with poorly man-
aged diabetes mellitus for 20 years, and he was on Insulin 
Mixtard 30/70.
On his admission, the patient did not complain of any 
gastrointestinal Tract (GIT), urinary or respiratory dis-
orders, but was very ill and feverish. Within 48  h post 
admission he rapidly deteriorated into a coma state; Glas-
gow coma scale of 6 and did not react to stimuli with sig-
nificant neck stiffness. He was admitted to the intensive 
care unit and was suspected of meningitis. Lumbar punc-
ture was not performed since the patient had spinal cord 
disc prolapse. Brain CT scan was unremarkable. Several 
biochemical and haematological tests and blood film for 
malaria were performed. The renal and liver parameters 
were within the normal range. The patient had a fast-
ing blood sugar of 295 mg/dl, haemoglobin of 11 g/dl, a 
platelet count of 43,000 cells/mm3, erythrocyte sedimen-
tation rate (ESR) 18 mm, and a total white blood count of 
13.4000 cells/mm3.
Blood film for malaria parasites was positive by light 
microscopy for P. vivax (quantified as 3 +++). PCR 
amplified P. vivax specific band of 499 bp using Plasmo-
dium multi species multiplex PCR primers (Fig.  1). The 
patient was diagnosed as P. vivax cerebral malaria case. 
He was started on intravenous fluids, intravenous qui-
nine at the dose of 10 mg/kg body weight IV for 10 days 
and Ceftriaxone 1  g IV PD for 7  days, followed by pri-
maquine 15  mg/days PO for 2  weeks. The vital signs 
improved over the next 48  h. The patient was released 
from the hospital 12 days post admission.
Discussion and conclusions
The incidence of P. vivax infection is rising in Sudan and 
has increased from about 5% in 2013 to 26% of the total 
malaria cases [3]. Although severe P. vivax cases were 
reported from many endemic areas in South East Asia, 
the Pacific islands and South America, a few cases were 
reported in Africa reflecting the neglected status of P. 
vivax in Africa [2].
The patient described in the report was living in Khar-
toum the capital city of Sudan where malaria trans-
mission is seasonal and non-endemic of P. vivax until 
recently. The fact that he was a known type 2 diabetic 
patients, presenting with high grade fever, chills, vomit-
ing, sweating and confusion lead to suspicion of serious 
infections, including meningitis and falciparum malaria, 
which is the common cause of severe malaria in Sudan 
[5]. The rapid deterioration of the patient into coma and 
stiffness within 48 h of his admission increased the sus-
picion of meningitis and cerebral malaria and required 
Fig. 1 Polymerase chain reaction amplification of Plasmodium vivax 
DNA of the blood sample from the patient showing amplification of 
499 bp amplicon characteristic of P. vivax. Lane1: Molecular weight 
standard 100 bp, lane 2 positive P. vivax control, lane 3: patient’s 
sample
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his admission to the Intensive Care Unit (ICU). Cases of 
bacterial and viral meningitis were previously reported in 
Khartoum [6]. Lumbar puncture was recommended but 
the procedure was not performed since the patient had 
spinal cord disc making it a risky procedure. The nega-
tive finding of the CT scan excluded the possibility of 
central nervous system disease. The normal results of 
laboratory investigations including renal and liver param-
eters excluded renal and liver diseases. The lack of GIT 
and respiratory complain make the possibility of enteric 
infection and pulmonary TB less likely. On the other 
hand, the slight increase of the WBC suggested inflam-
matory reaction, while the low platelet counts increased 
the suspicion of severe infection including cerebral 
malaria. The finding of the blood film was decisive and 
demonstrated malaria parasite with high parasitaemia 
(+++), close examination of the thin films identified 
P. vivax infection which was confirmed by the positive 
result of Plasmodium multi species PCR [7]. Interest-
ingly, most of the severe P. vivax malaria reported in 
other endemic areas including those in children in east-
ern Sudan were accompanied by low parasitaemia con-
trary to the findings of this study [8]. The fact that the 
patient was a known type 2 diabetes patient might had 
impaired his immune response leading to the increase 
in the parasite replication. It is worth noting that, this 
patient had an attack of severe P. vivax malaria 3 months 
before his current illness. He presented with fever, chills 
and confusion. He was successfully treated with quinine 
10 mg/kg body weight IV for 10 days, ceftazidime 1G IV 
8 hourly for 7 days followed by primaquine 15 mg/days 
PO for 2 weeks evident by the negative blood film at the 
end of the treatment course. The recent attack could be 
a recurrent attack since P. vivax prevails at low parasi-
taemia making its detection difficult [9]. It is worth not-
ing that no previous report on P. vivax drug resistance in 
Sudan, however the possibility of noncompliance to pri-
maquine treatment could be excluded strengthening the 
possibility of the persistent of the parasite from the first 
infection [10].
This report identified P. vivax as a cause of cerebral 
malaria in adults in Sudan and recommends considering 
P. vivax in the differential diagnosis of cerebral malaria 
caused by P. falciparum that requires a different treat-
ment regimen. Plasmodium vivax treatment should be 
closely supervised to assure cure of the infection.
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